News Sentiment

COGT sentiment intelligence

Cogent Biosciences Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 54 Balanced news tone 65 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 39.08 Week of 17 Jul 2026
Weighted tone 54/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

83/100 classification confidence.

Company focus 57

directly relevant articles

Source quality 3

high-authority source matches

Trend context Trend inactive

+0.5% over one week, +13.1% over four weeks, trend inactive, and materially above fair value.

Latest direct headline Neutral

COGT6232219 Bond Risk Profile

Market Reaction

Balanced read

54/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 83/100 classification
One-week reaction 0.5% Price digesting
Trend fit Trend inactive 13.1% over four weeks
Fair value 155.6% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 16
Neutral 43
Negative 6

Relevance

Why the article matched

Direct first
Direct company coverage 57
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 15
TradingView 10
Stock Titan 6
GlobeNewswire 4
Sahm 3
Moomoo 3
simplywall.st 3
Stock Traders Daily 2

Event Lens

What the news is about

Classified themes
Market update 42
Earnings 15
Balance sheet 3
Analyst action 2
Regulatory and legal 2
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-60 of 65
Insider Monkey Direct company coverage

Cogent (COGT) Presents Preclinical Data for Novel JAK2 Inhibitor CGT1145 at 2026 EHA Congress

Cogent Biosciences Inc. (NASDAQ: COGT) presented promising preclinical data for its novel JAK2 V617F inhibitor, CGT1145, at the 2026 EHA Congress. This candidate, designed to be a best-in-class therapy, shows high selectivity and oral bioavailability, aiming to treat myeloprolife

Tone
Positive 74/100
Event
Market update
Published
24 Jun 2026 14:10
Source
Insider Monkey
Market source Direct company coverage

Is Cogent Biosciences (COGT) ’s New Cancer Drug 100 Times More Precise Than What’s Already on the Market?

Cogent Biosciences (COGT) has unveiled early-stage preclinical data for its experimental drug CGT1145, presented as a potentially more precise and better-tolerated treatment for certain rare blood cancers. Lab results indicate CGT1145 is over 100-fold selective for a specific gen

Tone
Positive 74/100
Event
Earnings
Published
22 Jun 2026 14:11
Source
Market source
Simply Wall Street Direct company coverage

New Bezuclastinib and JAK2 Data Could Be A Game Changer For Cogent Biosciences (COGT)

Cogent Biosciences presented new data for bezuclastinib in advanced systemic mastocytosis and preclinical results for CGT1145 (a JAK2 V617F inhibitor) at the 2026 European Hematology Association Congress. These findings support bezuclastinib's potential as a multi-indication ther

Tone
Positive 67/100
Event
Earnings
Published
21 Jun 2026 06:40
Source
Simply Wall Street